TYK Medicines Inc 2024 AR2
The report highlights TYK Medicines, Inc.'s listing on the Stock Exchange of Hong Kong on August 20, 2024, and its clinical advancements in targeted cancer therapies, particularly its core product TY-9591. The company established a comprehensive ESG governance framework overseen by its Board of Directors and implemented various energy-saving and emission-reduction measures. In 2024, the company achieved 100% compliant wastewater and air emissions, and actively engaged in community co-construction and charitable donations, including a RMB 5 million scholarship to Zhengzhou University.
Company: TYK Medicines Inc
Sector: Health Care
Country: China
Year: 2024
Type: AR2
Pages: 209
TYK Medicines Inc
Annual Report
The report highlights TYK Medicines, Inc.'s listing on the Stock Exchange of Hong Kong on August 20, 2024, and its clinical advancements in targeted cancer therapies, particularly its core product TY-9591. The company established a comprehensive ESG governance framework overseen by its Board of Directors and implemented various energy-saving and emission-reduction measures. In 2024, the company achieved 100% compliant wastewater and air emissions, and actively engaged in community co-construction and charitable donations, including a RMB 5 million scholarship to Zhengzhou University.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Mar 27, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees